Abstract:Cannabis use disorder (CanUD) has increased with the legalization of the use of cannabis. Around 20% of individuals using cannabis develop CanUD, and the number of users has grown with increasing ease of access. CanUD and other substance use disorders (SUDs) are associated phenotypically and genetically. We leveraged new CanUD genomics data to undertake genetically-informed analyses with unprecedented power, to investigate the genetic architecture and causal relationships between CanUD and lifetime cannabis use with risk for developing SUDs and substance use traits. Analyses included calculating local and global genetic correlations, genomic structural equation modeling (genomicSEM), and Mendelian Randomization (MR). Results from the genetic correlation and genomicSEM analyses demonstrated that CanUD and cannabis use differ in their relationships with SUDs and substance use traits. We found significant causal effects of CanUD influencing all the analyzed traits: opioid use disorder (OUD) (Inverse variant weighted, IVW β = 0.925 ± 0.082), problematic alcohol use (PAU) (IVW β = 0.443 ± 0.030), drinks per week (DPW) (IVW β = 0.182 ± 0.025), Fagerström Test for Nicotine Dependence (FTND) (IVW β = 0.183 ± 0.052), cigarettes per day (IVW β = 0.150 ± 0.045), current versus former smokers (IVW β = 0.178 ± 0.052), and smoking initiation (IVW β = 0.405 ± 0.042). We also found evidence of bidirectionality showing that OUD, PAU, smoking initiation, smoking cessation, and DPW all increase risk of developing CanUD. For cannabis use, bidirectional relationships were inferred with PAU, smoking initiation, and DPW; cannabis use was also associated with a higher risk of developing OUD (IVW β = 0.785 ± 0.266). GenomicSEM confirmed that CanUD and cannabis use load onto different genetic factors. We conclude that CanUD and cannabis use can increase the risk of developing other SUDs. This has substantial public health implications; the move towards legalization of cannabis use may be expected to increase other kinds of problematic substance use. These harmful outcomes are in addition to the medical harms associated directly with CanUD.

Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking

Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking

Cracking the chicken and egg problem of schizophrenia and substance use: Genetic interplay between schizophrenia, cannabis use disorder, and tobacco smoking

Genome-wide Identification of the Shared Genetic Basis of Cannabis and Cigarette Smoking and Schizophrenia Implicates NCAM1 and Neuronal Abnormality.

GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability

Cigarette Smoking and Schizophrenia: Mendelian Randomisation Study.

S003329172000272Xjra 968..978

Genetic correlation, pleiotropy, and causal associations between substance use and psychiatric disorder

Multi-ancestry meta-analysis of tobacco use disorder identifies 461 potential risk genes and reveals associations with multiple health outcomes

Brain-wide pleiotropy investigation of alcohol drinking and tobacco smoking behaviors

The genetic architecture of substance use and its diverse correlations with mental health traits

Genetic influences and causal pathways shared between cannabis use disorder and other substance use traits

Identification of 34 genes conferring genetic and pharmacological risk for the comorbidity of schizophrenia and smoking behaviors

Shared and unique 3D genomic features of substance use disorders across multiple cell types

Combining Transdiagnostic and Disorder-Level GWAS Enhances Precision of Psychiatric Genetic Risk Profiles in a Multi-Ancestry Sample

Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use

A multi-ancestry cerebral cortex transcriptome-wide association study identifies genes associated with smoking behaviors

Genome-wide Association Study of Lifetime Cannabis Use Based on a Large Meta-Analytic Sample of 32 330 Subjects from the International Cannabis Consortium

Characterising the shared genetic determinants of bipolar disorder, schizophrenia and risk-taking

An Association Study Revealed Substantial Effects of Dominance, Epistasis and Substance Dependence Co‐morbidity on Alcohol Dependence Symptom Count